Nasdaq:BMRN
BIOMARIN PHARMACEUTICAL INC
Biogen is a leading biopharmaceutical innovator focused on treating neurodegenerative diseases with a robust pipeline of high-value therapeutics.
Key Metrics
Investment Thesis
Bull Case
Investors may find value in Biogen due to its market-leading position in Alzheimer's disease with Leqembi, which has the potential to generate significant revenue over its remaining patent life. The company's diversified portfolio of rare disease therapies provides a stable baseline of cash flow that can support ongoing research and development efforts. Strong balance sheet metrics, including $1.31B in cash equivalents, offer financial flexibility for M&A or strategic acquisitions.
Bear Case
Potential investors should be cautious regarding the high capital expenditures of $103M and substantial R&D spend of $921.9M, which could strain liquidity if new product approvals do not materialize as expected. The company's reliance on a few blockbuster drugs exposes it to significant revenue volatility if competitors launch comparable therapies or if access is restricted by payers. Historical data shows net income variability, suggesting earnings quality may be sensitive to one-time charges or commercial headwinds.
About BIOMARIN PHARMACEUTICAL INC
Biogen is a global biopharmaceutical company specializing in neurodegenerative and rare diseases, with key products including Leqembi for Alzheimer's disease. The company serves markets across the United States, Europe, and Asia-Pacific, focusing on delivering innovative therapies that address unmet medical needs. Recent financial data highlights strong revenue growth driven by its commercial portfolio expansion.
Analysis
Management Discussion
Management executed a strong commercial strategy, driving revenue from $2.10B in 2022 to $3.22B in the latest period, reflecting successful product launches and market penetration. While net income fluctuated between $141.6M and $426.9M over the review period, the company maintained healthy cash flow from operations of $828.0M to fund its substantial R&D investments exceeding $900M annually.
Industry Overview
The global biopharmaceutical industry is characterized by rapid innovation in neurodegenerative disease treatments and increasing competition from large tech firms entering the healthcare space. Companies in this sector face high barriers to entry due to the need for extensive clinical trial data and regulatory approval, favoring established players with deep pockets. Regulatory bodies are increasingly scrutinizing pricing models and real-world evidence requirements, impacting the profitability landscape for all major competitors.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $2.10B | $2.42B | $2.85B | $3.22B |
| Cost of Revenue | $483.7M | $514.9M | $580.2M | $717.4M |
| Gross Profit | $1.61B | $1.90B | $2.27B | $2.50B |
| Operating Expenses | $1.46B | $1.75B | $1.79B | $2.09B |
| Operating Income | $149.6M | $158.1M | $484.2M | $409.5M |
| R&D | $649.6M | $746.8M | $747.2M | $921.9M |
| G&A | $854.0M | $937.3M | $1.01B | $1.15B |
| Stock-Based Comp | $196.3M | $207.1M | $201.6M | $181.4M |
| D&A | $102.0M | $104.4M | $96.4M | $79.6M |
| Depreciation | $38.6M | $40.3M | $46.6M | $48.5M |
| Amortization | — | — | $43.3M | $19.4M |
| Other OpEx | $-40.8M | $62.2M | $33.3M | $19.4M |
| Non-Operating Income | $14.0K | $30.5M | $57.5M | $73.0M |
| Interest Expense | $16.0M | $17.3M | — | — |
| Interest Income | $18.0M | $58.3M | $74.9M | $74.9M |
| Pre-Tax Income | $149.6M | $188.6M | $541.8M | $482.5M |
| Income Tax | $8.0M | $20.9M | $114.9M | $133.6M |
| Continuing Ops | $141.6M | $167.6M | $426.9M | $348.9M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $141.6M | $167.6M | $426.9M | $348.9M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $141.6M | $167.6M | $426.9M | $348.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $2.75B | $2.96B | $3.23B | $3.95B |
| Cash & Equivalents | $724.5M | $755.1M | $942.8M | $1.31B |
| Accounts Receivable | $461.3M | $633.7M | $660.5M | $908.2M |
| Inventory | $894.1M | $1.11B | $1.23B | $1.30B |
| Other Current Assets | $671.5M | $460.1M | $396.4M | $434.7M |
| Long-Term Assets | $3.62B | $3.89B | $3.76B | $3.64B |
| PP&E (Net) | $1.07B | $1.07B | $1.04B | $952.5M |
| Intangibles | $338.6M | $294.7M | $255.3M | $213.8M |
| Goodwill | $196.2M | $196.2M | $196.2M | $196.2M |
| Operating Leases | $34.9M | $42.7M | $28.7M | $35.2M |
| Other LT Assets | $1.98B | $2.29B | $2.23B | $2.24B |
| Total Assets | $6.38B | $6.84B | $6.99B | $7.59B |
| Current Liabilities | $588.9M | $1.18B | $607.0M | $759.0M |
| Current Leases | $8.1M | $8.6M | $7.2M | $8.6M |
| Deferred Revenue | $711.0K | $4.6M | $1.4M | — |
| Taxes Payable | $16.2M | $2.7M | $12.6M | $3.7M |
| Other Current Liab | $563.9M | $1.16B | $585.8M | $746.8M |
| Long-Term Liabilities | $1.18B | $713.0M | $724.0M | $748.0M |
| LT Operating Leases | $26.3M | $38.0M | $30.5M | $36.6M |
| Other LT Liab | $1.16B | $675.0M | $693.5M | $711.4M |
| Total Liabilities | $1.77B | $1.89B | $1.33B | $1.51B |
| Shareholders' Equity | $4.60B | $4.95B | $5.66B | $6.09B |
| Retained Earnings | $-789.2M | $-621.6M | $-194.7M | $154.2M |
| AOCI | $-3.9M | $-28.8M | $61.7M | $-13.5M |
| Total L&E | $6.38B | $6.84B | $6.99B | $7.59B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $141.6M | $167.6M | $426.9M | $348.9M |
| Non-Cash Adjustments | $-193.9M | $-529.8M | $-35.5M | $23.4M |
| Working Capital Changes | $228.3M | $521.4M | $181.4M | $455.7M |
| Cash from Operations | $175.9M | $159.3M | $572.8M | $828.0M |
| Capital Expenditures | $121.0M | $96.7M | $85.4M | $103.0M |
| Cash from Investing | $-20.0M | $-111.2M | $136.5M | $-414.2M |
| Share Buybacks | $0 | — | — | — |
| Cash from Financing | $-18.6M | $-18.7M | $-526.4M | $-42.4M |
| FX Effect | $32.0K | $1.3M | $4.8M | $-2.5M |
| Net Change in Cash | $137.3M | $30.6M | $187.7M | $368.8M |
| Beginning Cash | $587.3M | $724.5M | $755.1M | $942.8M |
| Ending Cash | $724.5M | $755.1M | $942.8M | $1.31B |
Frequently Asked Questions
How does BIOMARIN PHARMACEUTICAL INC make money?
The company's revenue is primarily derived from its Commercial segment, which includes sales of approved products like Leqembi and Aduhelm for Alzheimer's, as well as other therapies for rare genetic diseases. Operations are further supported by strategic collaborations and licensing agreements that generate royalty income and milestone payments from external partners.
What are the main risks for BMRN?
The biopharmaceutical industry faces intense patent cliffs that could erode revenue streams once key exclusivity periods expire without successful follow-on approvals. Regulatory uncertainty regarding reimbursement policies in major markets like the US and EU poses a risk to pricing power and market access for high-cost therapies. Clinical trial failures for new asset candidates could lead to significant write-offs and delay strategic growth plans.
What is BMRN's competitive advantage?
Biogen possesses a deep scientific expertise in neurodegenerative disease mechanisms, providing a significant first-to-market advantage with Leqembi in the Alzheimer's treatment space. The company benefits from an extensive global commercial infrastructure capable of scaling distribution for complex biologics and rare disease therapies. A robust pipeline of late-stage development candidates further strengthens its long-term value proposition.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.